Matches in DBpedia 2016-04 for { ?s ?p "The combination drug tegafur/gimeracil/oteracil (trade name Teysuno, and TS-1 in Japan), also known as S-1, is used for the treatment of advanced gastric cancer. It is labelled for use in combination with cisplatin in many European countries, and for head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers in several countries in Asia. It has not been approved by the FDA.It is also being developed for the treatment of hepatocellular carcinoma. and has activity in esophageal,(Perry Chapter 33) breast, cervical, and colorectal cancer.Within the medication, the molar ratio of the three components (tegafur:gimeracil:oteracil) is 1:1:0.4.The maximum tolerated dose differed between Asian and Caucasian populations (80 mg/m2 and 25 mg/m2 respectively), perhaps due to differences in CYP2A6 genotype."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- oteracil abstract "The combination drug tegafur/gimeracil/oteracil (trade name Teysuno, and TS-1 in Japan), also known as S-1, is used for the treatment of advanced gastric cancer. It is labelled for use in combination with cisplatin in many European countries, and for head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers in several countries in Asia. It has not been approved by the FDA.It is also being developed for the treatment of hepatocellular carcinoma. and has activity in esophageal,(Perry Chapter 33) breast, cervical, and colorectal cancer.Within the medication, the molar ratio of the three components (tegafur:gimeracil:oteracil) is 1:1:0.4.The maximum tolerated dose differed between Asian and Caucasian populations (80 mg/m2 and 25 mg/m2 respectively), perhaps due to differences in CYP2A6 genotype.".
- Q15410179 abstract "The combination drug tegafur/gimeracil/oteracil (trade name Teysuno, and TS-1 in Japan), also known as S-1, is used for the treatment of advanced gastric cancer. It is labelled for use in combination with cisplatin in many European countries, and for head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers in several countries in Asia. It has not been approved by the FDA.It is also being developed for the treatment of hepatocellular carcinoma. and has activity in esophageal,(Perry Chapter 33) breast, cervical, and colorectal cancer.Within the medication, the molar ratio of the three components (tegafur:gimeracil:oteracil) is 1:1:0.4.The maximum tolerated dose differed between Asian and Caucasian populations (80 mg/m2 and 25 mg/m2 respectively), perhaps due to differences in CYP2A6 genotype.".